Max Robotics — Global Service Robot Directory + US Certification

About

Andreas Obermair is a leading gynaecological oncologist whose research has reshaped surgical standards for cervical and endometrial cancers. His landmark 2018 study in the *New England Journal of Medicine*—comparing minimally invasive versus abdominal radical hysterectomy for early-stage cervical cancer—garnered over 1,850 citations and fundamentally challenged the prevailing shift toward laparoscopic and robotic approaches. By demonstrating inferior survival outcomes with minimally invasive surgery, this work prompted urgent re-evaluation of surgical protocols worldwide. Obermair also spearheaded the LACC trial (2008), a phase III randomised study that laid critical groundwork for evidence-based surgical decision-making. His ongoing ENDO-3 trial (2021) investigates sentinel node biopsy versus no retroperitoneal dissection in endometrial cancer, aiming to reduce morbidity without compromising oncologic safety. Beyond these major trials, he has explored patient-centred factors influencing hysterectomy decisions and the cost-efficiency of robotic surgery. With over 2,000 combined citations across his most influential works, Obermair’s contributions continue to drive rigorous, patient-focused innovation in gynaecologic oncology, challenging assumptions and improving outcomes for women worldwide.